Skip to content

Application of human health management system based on big data in antithrombotic treatment of coronary heart disease

Application of human health management system based on big data in antithrombotic treatment of coronary heart disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900028125
Enrollment
Unknown
Registered
2019-12-13
Start date
2017-10-01
Completion date
Unknown
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic heart disease

Interventions

1:non-invasive intervention
2:antiplatelet drugs
3:Herbal medications
4:life style change

Sponsors

Cardiovascular Surgery, the First Medical Center, General Hospital of the People's Liberation Army of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: According to the characteristics of coronary heart disease and clinical diagnosis and treatment in China, 1500 patients with coronary heart disease, 1500 patients with coronary heart disease after PCI and 1500 patients with coronary heart disease after coronary artery bypass grafting are proposed to be included. The patients are distributed in the eastern and western regions of China, coastal and inland cities, including the ages under 40, 40-60 and over 60 Layer. Patients with diabetes and renal insufficiency should be studied as a subgroup.

Exclusion criteria

Exclusion criteria: Patients with systemic active infection; patients with severe hepatorenal insufficiency (ALT > 135mmol / L, Cr > 200umol / L) or chronic obstructive pulmonary disease; patients with obvious bleeding tendency and hematologic diseases; patients with malignant tumors and end-stage diseases; patients with life expectancy less than 6 months; patients with heart valve or left ventricular aneurysm and other diseases requiring simultaneous operation; patients with cerebrovascular diseases (at present or within six months, there has been cerebral infarction or cerebral hemorrhage); recently participated in the trial drug research but failed to complete the main end point or clinically hindered the clinical research end point.

Design outcomes

Primary

MeasureTime frame
Thromboembolic events;Bleeding events;

Secondary

MeasureTime frame
Pulse wave detection;24 channel bioelectrical impedance measurement;Coagulation and platelet function;

Countries

China

Contacts

Public ContactRong Wang

Cardiovascular Surgery, the First Medical Center, General Hospital of the People's Liberation Army of China

wangrongd@126.com+86 15801371359

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026